The research company Chosa Oncology presented positive data from its collaboration with international lung cancer experts within the European Thoracic Oncology Platform and the European Organisation for Research and Treatment of Cancer, at the lung cancer congress European Lung Cancer Congress in Köpenhamn. This is stated in a press release. The project evaluates Chosa's Platin-DRP in patients with advanced non-small cell lung cancer treated with platinum-based chemotherapy in the phase III study Splendour. The translational analysis included 82 patients, of whom 28 were treated with cisplatin and 54 with carboplatin.The data presented at the congress showed that in the pooled cohort, higher Platin-DRP scores were associated with a statistically significant improvement in both progression-free survival and overall survival. Importantly, overall survival showed the strongest association, the company emphasizes.